LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Device That Detects Cancer Cells Could Help Avoid Invasive Biopsy Surgeries

By LabMedica International staff writers
Posted on 28 Feb 2023
Image: The Static Droplet Microfluidic device rapidly detects circulating tumor cells in the bloodstream (Photo courtesy of UTS)
Image: The Static Droplet Microfluidic device rapidly detects circulating tumor cells in the bloodstream (Photo courtesy of UTS)

Cancer is a major contributor to illness and death, and those with suspected cancer may need surgery for a diagnosis, especially for liver, colon or kidney tumors. Unfortunately, biopsies can be uncomfortable, costly, and increase the risk of complications due to surgery. To resolve this problem, researchers have created a new device that can detect and analyze cancer cells from blood samples. This could eliminate the need for a biopsy surgery, as well as allow doctors to monitor treatment progress more accurately.

Researchers from the University of Technology Sydney (UTS, Sydney, Australia) have developed the Static Droplet Microfluidic device, which can quickly detect tumor cells that have migrated away from a primary tumor and into the bloodstream. The device utilizes a distinctive metabolic signature of cancer to separate tumor cells from regular blood cells. After tumor cells are located with the device, they can then be studied genetically and molecularly to support diagnosis and classification of the cancer, allowing for more personalized treatment options.

Circulating tumor cells are a precursor of metastasis, which is responsible for approximately 90% of all cancer-related deaths. Studying these cells may offer greater understanding of the biology behind cancer metastasis, which can help in the development of new treatments. The current liquid biopsy solutions are slow, expensive, and require specialist operators, restricting their use in clinical settings. This new technology is designed to be integrated into research and clinical labs without needing expensive and complex equipment or a trained operator, making it practical and cost-effective for doctors to diagnose and monitor cancer patients.

“Managing cancer through the assessment of tumor cells in blood samples is far less invasive than taking tissue biopsies. It allows doctors to do repeat tests and monitor a patient’s response to treatment,” said Professor Majid Warkiani from the UTS School of Biomedical Engineering.

Related Links:
University of Technology Sydney 

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more